NO20080249L - Transglutaminaseformidlet konjugasjon av veksthormon - Google Patents
Transglutaminaseformidlet konjugasjon av veksthormonInfo
- Publication number
- NO20080249L NO20080249L NO20080249A NO20080249A NO20080249L NO 20080249 L NO20080249 L NO 20080249L NO 20080249 A NO20080249 A NO 20080249A NO 20080249 A NO20080249 A NO 20080249A NO 20080249 L NO20080249 L NO 20080249L
- Authority
- NO
- Norway
- Prior art keywords
- growth hormone
- transglutaminase
- conjugation
- mediated growth
- functional group
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 5
- 108010051696 Growth Hormone Proteins 0.000 title abstract 5
- 239000000122 growth hormone Substances 0.000 title abstract 5
- 108060008539 Transglutaminase Proteins 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000003601 transglutaminase Human genes 0.000 title 1
- 125000000524 functional group Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 101710123874 Protein-glutamine gamma-glutamyltransferase Proteins 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
Abstract
Fremgangsmåte for PEGylering av veksthormon, hvor fremgangsmåten omfatter å omsette veksthormon med en aminomfattende nukleofil, som videre omfatter en første funksjonell gruppe, i nærvær av TGase for å danne et transaminert veksthormon, etterfulgt av en omsetning av det transaminerte veksthormon med en PEG som er blitt funksjonalisert med en andre funksjonell gruppe, hvor den første og den andre funksjonelle gruppen er valgt slik at de reagerer, hvorved det dannes en kovalent binding.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05105256 | 2005-06-15 | ||
EP05109667 | 2005-10-18 | ||
PCT/EP2006/063246 WO2006134148A2 (en) | 2005-06-15 | 2006-06-15 | Transglutaminase mediated conjugation of growth hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20080249L true NO20080249L (no) | 2008-03-17 |
Family
ID=37031113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080249A NO20080249L (no) | 2005-06-15 | 2008-01-14 | Transglutaminaseformidlet konjugasjon av veksthormon |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100197573A1 (no) |
EP (1) | EP1893239A2 (no) |
JP (1) | JP2008543297A (no) |
KR (1) | KR20080016674A (no) |
AU (1) | AU2006259080A1 (no) |
BR (1) | BRPI0611570A2 (no) |
CA (1) | CA2612794A1 (no) |
IL (1) | IL187630A0 (no) |
MX (1) | MX2007015676A (no) |
NO (1) | NO20080249L (no) |
RU (1) | RU2007145085A (no) |
TW (1) | TW200716179A (no) |
WO (1) | WO2006134148A2 (no) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2008105545A (ru) | 2005-08-30 | 2009-10-10 | Ново Нордиск Хелс Кеа Аг (Ch) | Жидкие препараты пэгилированного гормона роста |
CN101495155A (zh) | 2006-07-07 | 2009-07-29 | 诺沃-诺迪斯克保健股份有限公司 | 新的蛋白结合物及其制备方法 |
CA2672651C (en) | 2006-12-15 | 2014-03-11 | Lifebond Ltd. | Gelatin-transglutaminase hemostatic dressings and sealants |
CA2678669A1 (en) * | 2007-02-22 | 2008-08-28 | Novo Nordisk Health Care Ag | Transglutaminase variants with improved specificity |
US9272048B2 (en) * | 2008-04-29 | 2016-03-01 | Ascendis Pharma Growth Disorders Division A/S | PEGylated recombinant human growth hormone compounds |
US8367388B2 (en) | 2008-06-18 | 2013-02-05 | Lifebond Ltd. | Cross-linked compositions |
WO2010029107A1 (en) * | 2008-09-09 | 2010-03-18 | Novo Nordisk Health Care Ag | Growth hormone conjugate with increased stability |
EP2427215A1 (en) * | 2009-05-07 | 2012-03-14 | Novo Nordisk Health Care AG | Stable pharmaceutical compositions of peptide derivatized using an oxime linker |
CN102612376A (zh) * | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
JP5796860B2 (ja) | 2009-12-22 | 2015-10-21 | ライフボンド リミテッドLifebond Ltd | 架橋マトリックスの特性を調節するための酵素的架橋剤の改変 |
CN106139158A (zh) | 2010-01-22 | 2016-11-23 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
ITPD20100155A1 (it) | 2010-05-19 | 2011-11-20 | Univ Padova | Metodo per la preparazione di coniugati mediante transglutaminasi |
CA2807012A1 (en) | 2010-08-05 | 2012-02-09 | Lifebond Ltd. | Dry composition wound dressings and adhesives |
MX2013009862A (es) | 2011-03-02 | 2013-10-25 | Novo Nordisk As | Factor de coagulacion dirigido al transcripto 1 tipo trem (tlt-1) en plaquetas activadas. |
TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
CN105209497B (zh) | 2013-03-15 | 2021-09-07 | 诺和诺德股份有限公司 | 能够特异性结合组织因子途径抑制物上的两个表位的抗体 |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
ES2756526T3 (es) * | 2013-07-11 | 2020-04-27 | Novartis Ag | Modificaciones de proteínas quimioenzimáticas específicas para lisina utilizando transglutaminasa microbiana |
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
JP2021502068A (ja) | 2017-11-07 | 2021-01-28 | コデクシス, インコーポレイテッド | トランスグルタミナーゼバリアント |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
WO1996010089A1 (fr) | 1994-09-29 | 1996-04-04 | Ajinomoto Co., Inc. | Modification d'un peptide et d'une proteine |
US6620916B1 (en) | 1996-09-26 | 2003-09-16 | Ajinomoto Co., Inc. | Modified physiologically active proteins and medicinal compositions containing the same |
EP1352062A2 (en) * | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
KR20060032140A (ko) * | 2003-05-30 | 2006-04-14 | 센토코 인코포레이티드 | 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성 |
CN1243022C (zh) * | 2003-10-17 | 2006-02-22 | 华东师范大学 | 生物修饰重组人生长激素复合物及其制备方法 |
ES2397241T3 (es) * | 2004-01-21 | 2013-03-05 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
ATE542920T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
RU2008105545A (ru) * | 2005-08-30 | 2009-10-10 | Ново Нордиск Хелс Кеа Аг (Ch) | Жидкие препараты пэгилированного гормона роста |
-
2006
- 2006-06-15 JP JP2008516324A patent/JP2008543297A/ja not_active Withdrawn
- 2006-06-15 EP EP06763740A patent/EP1893239A2/en not_active Withdrawn
- 2006-06-15 MX MX2007015676A patent/MX2007015676A/es not_active Application Discontinuation
- 2006-06-15 AU AU2006259080A patent/AU2006259080A1/en not_active Abandoned
- 2006-06-15 RU RU2007145085/04A patent/RU2007145085A/ru unknown
- 2006-06-15 US US11/917,364 patent/US20100197573A1/en not_active Abandoned
- 2006-06-15 TW TW095121367A patent/TW200716179A/zh unknown
- 2006-06-15 BR BRPI0611570-5A patent/BRPI0611570A2/pt not_active IP Right Cessation
- 2006-06-15 WO PCT/EP2006/063246 patent/WO2006134148A2/en active Application Filing
- 2006-06-15 KR KR1020077030258A patent/KR20080016674A/ko not_active Application Discontinuation
- 2006-06-15 CA CA002612794A patent/CA2612794A1/en not_active Abandoned
-
2007
- 2007-11-26 IL IL187630A patent/IL187630A0/en unknown
-
2008
- 2008-01-14 NO NO20080249A patent/NO20080249L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006134148A2 (en) | 2006-12-21 |
MX2007015676A (es) | 2008-02-20 |
RU2007145085A (ru) | 2009-07-20 |
EP1893239A2 (en) | 2008-03-05 |
IL187630A0 (en) | 2008-03-20 |
KR20080016674A (ko) | 2008-02-21 |
US20100197573A1 (en) | 2010-08-05 |
CA2612794A1 (en) | 2006-12-21 |
WO2006134148A3 (en) | 2007-12-21 |
JP2008543297A (ja) | 2008-12-04 |
AU2006259080A1 (en) | 2006-12-21 |
TW200716179A (en) | 2007-05-01 |
BRPI0611570A2 (pt) | 2011-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080249L (no) | Transglutaminaseformidlet konjugasjon av veksthormon | |
GB2446088B (en) | Production of conjugates | |
WO2007000343A3 (en) | Process for manufacturing vaccines | |
MXPA05006702A (es) | Hemoglobina modificada y metodos para hacer la misma. | |
WO2007062037A3 (en) | Compositions and methods of producing hybrid antigen binding molecules and uses thereof | |
MX2010001963A (es) | Procedimiento para la preparacion de 4-aminobut-2-enolidos. | |
TW200720274A (en) | Dna-pk inhibitors | |
MX2012001665A (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos. | |
TW200618796A (en) | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors | |
TW200510381A (en) | Novel 2-pyridinecarboxamide derivatives | |
HK1135096A1 (en) | Process for preparing 6-phenoxypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivative | |
WO2006076991A3 (de) | Verfahren zum herstellen eines feldeffekttransistors, feldeffekttransistor und integrierte schaltungsanordnung | |
NO20071710L (no) | Fremgangsmate for fremstilling av fenoksybenzamidforbindelser | |
DK1831239T5 (da) | Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-gamma-lacton og nøgle-mellemprodukter til denne fremgangsmåde | |
TW200508178A (en) | Process for continuously preparing alkylamino(meth)-acrylamides | |
UA87710C2 (ru) | Способ получения производных [1,4,5]-оксадиазепина | |
TW200740769A (en) | Novel process | |
IL188716A0 (en) | Method for preparing 4??-amino-4'-dimethyl-4- | |
EA200701852A1 (ru) | Производные аминокислот | |
TW200738650A (en) | Process for synthesis of aryloxy diaminopyrimidines | |
EP1967854B8 (en) | Method for determining the amount of conjugated taxane in polyglutamic acid-taxane conjugates | |
IL179141A (en) | Biotransformation of colchicinoid compounds | |
DK1501838T3 (da) | Fremgangsmåde til fremstilling af clopidogrel | |
MXPA05013604A (es) | Procedimiento para preparar acilsulfamoilbenzamidas. | |
TW200635914A (en) | Process for preparing substituted thiophenesulfonyl isocyanates |